Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria
- 1 August 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (8) , 2084-2088
- https://doi.org/10.1128/aac.42.8.2084
Abstract
The in vitro activities of seven quinolones and the sequences of the quinolone resistance-determining regions (QRDR) in the A and B subunits of DNA gyrase were determined for 14 mycobacterial species. On the basis of quinolone activity, quinolones were arranged from that with the greatest to that with the least activity as follows: sparfloxacin, levofloxacin, ciprofloxacin, ofloxacin, pefloxacin, flumequine, and nalidixic acid. Based on MICs, the species could be organized into three groups: resistant (Mycobacterium avium, M. intracellulare, M. marinum,M. chelonae, M. abscessus [ofloxacin MICs, ≥8 μg/ml]), moderately susceptible (M. tuberculosis,M. bovis BCG, M. kansasii, M. leprae, M. fortuitum third biovariant, M. smegmatis [ofloxacin MICs, 0.5 to 1 μg/ml]), and susceptible (M. fortuitum, M. peregrinum, M. aurum [ofloxacin MICs, ≤0.25 μg/ml]). Peptide sequences of the QRDR of GyrB were identical in all the species, including the amino acids at the three positions known to be involved in acquired resistance to quinolone, i.e., 426 (Asp), 447 (Arg), and 464 (Asn) (numbering system used for Escherichia coli). The last two residues could be involved in the overall low level of susceptibility of mycobacteria to quinolones since they differ from those found in the very susceptible E. coli (Lys-447 and Ser-464) but are identical to those found in the less susceptible Staphylococcus aureus and Streptococcus pneumoniae. Peptide sequences of the QRDR of GyrA were identical in all the species, except for the amino acid at position 83, which was an alanine in the two less susceptible groups and a serine in the most susceptible one, as inE. coli, suggesting that this amino acid is involved in the observed differences of quinolone susceptibility within theMycobacterium genus.Keywords
This publication has 47 references indexed in Scilit:
- The Clinical Use of Fluoroquinolones for the Treatment of Mycobacterial DiseasesClinical Infectious Diseases, 1997
- Fluoroquinolone Resistance Associated with Specific Gyrase Mutations in Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosisThe Journal of Infectious Diseases, 1996
- Structure and mechanism of DNA topoisomerase IINature, 1996
- A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate ofSalmonella typhimuriumFEMS Microbiology Letters, 1995
- Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone‐resistant isolatesMolecular Microbiology, 1994
- Mycobacterial cell wall: Structure and role in natural resistance to antibioticsFEMS Microbiology Letters, 1994
- In-vitro activity of quinolones and macrolides against mycobacteriaJournal of Antimicrobial Chemotherapy, 1994
- In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosisTubercle, 1991
- A rapid method for the detection of potentially viableMycobacterium lepraein human biopsies: a novel application of PCRFEMS Microbiology Letters, 1989
- A rapid method for the detection of potentially viable Mycobacterium leprae in human biopsies: a novel application of PCRFEMS Microbiology Letters, 1989